亚宝药业集团股份有限公司 关于出售子公司股权进展 暨完成工商变更登记的公告

Transaction Overview - The company approved the sale of 62% equity in its subsidiary Taiyuan Pharmaceutical Co., Ltd. for RMB 87,188,740 on November 17, 2025 [1] - The decision was made during the 11th meeting of the 9th Board of Directors [1] Progress Update - As of December 19, 2025, the equity transfer registration has been completed, resulting in the company holding only 5% of Taiyuan Pharmaceutical [1] - Following this change, Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements [1]